EHA Library - The official digital education library of European Hematology Association (EHA)

DELAYED EFFECT OF G-CSF ON THE CYTOKINE SECRETION THROUGH G-CSF MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN CHILDREN WITH CEREBRAL PALSY
Author(s): ,
Young-Ho Lee
Affiliations:
Department of Pediatrics,HANYANG UNIVERSITY MEDICAL CENTER,Seoul,Korea, Republic Of;Blood & Marrow Transplantation Center,HANYANG UNIVERSITY MEDICAL CENTER,Seoul,Korea, Republic Of
,
Wee-Jin Rah
Affiliations:
Department of Pediatrics,HANYANG UNIVERSITY MEDICAL CENTER,Seoul,Korea, Republic Of
,
Hani Koh
Affiliations:
Department of Pediatrics,HANYANG UNIVERSITY MEDICAL CENTER,Seoul,Korea, Republic Of;Blood & Marrow Transplantation Center,HANYANG UNIVERSITY MEDICAL CENTER,Seoul,Korea, Republic Of
,
Hyun-Joo Jun
Affiliations:
Department of Pediatrics,HANYANG UNIVERSITY MEDICAL CENTER,Seoul,Korea, Republic Of
,
Jin Young Suh
Affiliations:
Blood & Marrow Transplantation Center,HANYANG UNIVERSITY MEDICAL CENTER,Seoul,Korea, Republic Of
,
Hye Jung Eom
Affiliations:
Blood & Marrow Transplantation Center,HANYANG UNIVERSITY MEDICAL CENTER,Seoul,Korea, Republic Of
Mi Jung Kim
Affiliations:
Department of Rehabilitation Medicine,HANYANG UNIVERSITY MEDICAL CENTER,Seoul,Korea, Republic Of
(Abstract release date: 05/18/17) EHA Library. Lee Y. 05/18/17; 182564; PB1850
Prof. Dr. Young-Ho Lee
Prof. Dr. Young-Ho Lee
Contributions
Abstract

Abstract: PB1850

Type: Publication Only

Background
Granulocyte colony-stimulating factor (G-CSF) has been widely used to mobilize peripheral blood stem cells. In addition, it also has been tried to reveal the regenerative potential in various neurodegenerative diseases.

Aims
We investigated the short-term and delayed effects of infused G-CSF for peripheral blood stem cell (PBSC) mobilization on the various cytokine secretions in children with cerebral palsy (CP).

Methods
G-CSF (10μg/kg/dose) was administered subcutaneously for 4 days to the children with CP. In first group, blood levels of G-CSF, interleukin (IL)-6, IL-10, insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), and brain derived neurotrophic factor (BDNF) as well as mobilized total nucleated cell (TNC)/CD34+ cell counts in peripheral blood were compared between just before G-CSF injection (D+0) and 1 day after 4 days of G-CSF injections (D+5). In second group, cytokine levels were compared between D+0 and 1 month after 4 days of G-CSF injection (D+30). Cytokine levels were measured by enzyme-linked immunosorbent assay.

Results
Baseline levels of G-CSF were significantly increased (p=0.000) and IGF-1 decreased (p=0.011) at D+5 after 4 days of G-CSF administration compared to control group. In contrast, other cytokine levels including IL-6, IL-10, VEGF, and BDNF did not show any significant changes between before and after G-CSF administration. CD34+ cell counts (p=0.000) as well as TNC counts (p=0.000) were significantly increased from D+0 to D+5 in children who received G-CSF compared to children received placebo. Regarding delayed effect of G-CSF administration, G-CSF levels were significantly increased from baseline to D+30 (p=0.000), along with the increase IL-10 (p=0.035) and VEGF levels (p=0.011) and the decrease of IGF-1levels (p=0.014).

Conclusion
G-CSF which administered to mobilize PBSCs could induce the delayed effects on the levels of G-CSF itself as well as of other cytokines which could affect on the neuroregenerative potential. Further studies would be warranted to reveal the mechanism and clinical significances of these delayed effect of G-CSF or mobilized PBSCs.

Session topic: 24. Gene therapy, cellular immunotherapy and vaccination

Keyword(s): Peripheral blood stem cell, G-CSF mobilization, Cytokine, Children

Abstract: PB1850

Type: Publication Only

Background
Granulocyte colony-stimulating factor (G-CSF) has been widely used to mobilize peripheral blood stem cells. In addition, it also has been tried to reveal the regenerative potential in various neurodegenerative diseases.

Aims
We investigated the short-term and delayed effects of infused G-CSF for peripheral blood stem cell (PBSC) mobilization on the various cytokine secretions in children with cerebral palsy (CP).

Methods
G-CSF (10μg/kg/dose) was administered subcutaneously for 4 days to the children with CP. In first group, blood levels of G-CSF, interleukin (IL)-6, IL-10, insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), and brain derived neurotrophic factor (BDNF) as well as mobilized total nucleated cell (TNC)/CD34+ cell counts in peripheral blood were compared between just before G-CSF injection (D+0) and 1 day after 4 days of G-CSF injections (D+5). In second group, cytokine levels were compared between D+0 and 1 month after 4 days of G-CSF injection (D+30). Cytokine levels were measured by enzyme-linked immunosorbent assay.

Results
Baseline levels of G-CSF were significantly increased (p=0.000) and IGF-1 decreased (p=0.011) at D+5 after 4 days of G-CSF administration compared to control group. In contrast, other cytokine levels including IL-6, IL-10, VEGF, and BDNF did not show any significant changes between before and after G-CSF administration. CD34+ cell counts (p=0.000) as well as TNC counts (p=0.000) were significantly increased from D+0 to D+5 in children who received G-CSF compared to children received placebo. Regarding delayed effect of G-CSF administration, G-CSF levels were significantly increased from baseline to D+30 (p=0.000), along with the increase IL-10 (p=0.035) and VEGF levels (p=0.011) and the decrease of IGF-1levels (p=0.014).

Conclusion
G-CSF which administered to mobilize PBSCs could induce the delayed effects on the levels of G-CSF itself as well as of other cytokines which could affect on the neuroregenerative potential. Further studies would be warranted to reveal the mechanism and clinical significances of these delayed effect of G-CSF or mobilized PBSCs.

Session topic: 24. Gene therapy, cellular immunotherapy and vaccination

Keyword(s): Peripheral blood stem cell, G-CSF mobilization, Cytokine, Children

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies